Novartis AG ADR (NVS)vsXeris Pharmaceuticals Inc (XERS)
NVS
Novartis AG ADR
$156.33
+1.37%
HEALTHCARE · Cap: $291.32B
XERS
Xeris Pharmaceuticals Inc
$7.93
+7.74%
HEALTHCARE · Cap: $1.40B
Smart Verdict
WallStSmart Research — data-driven comparison
Novartis AG ADR generates 17906% more annual revenue ($56.69B vs $314.85M). NVS leads profitability with a 22.5% profit margin vs 3.8%. NVS trades at a lower P/E of 23.1x. NVS earns a higher WallStSmart Score of 51/100 (C-).
NVS
Buy51
out of 100
Grade: C-
XERS
Avoid33
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-66.5%
Fair Value
$92.73
Current Price
$156.33
$63.60 premium
Intrinsic value data unavailable for XERS.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 31 in profit
Strong operational efficiency at 34.6%
Keeps 23 of every $100 in revenue as profit
Generating 5.6B in free cash flow
Revenue surging 38.3% year-over-year
Areas to Watch
0.8% revenue growth
Grey zone — moderate risk
Elevated debt levels
Expensive relative to growth rate
0.0% earnings growth
Smaller company, higher risk/reward
3.8% margin — thin
Premium valuation, high expectations priced in
Comparative Analysis Report
WallStSmart ResearchBull Case : NVS
The strongest argument for NVS centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 22.5% and operating margin at 34.6%.
Bull Case : XERS
The strongest argument for XERS centers on Revenue Growth. Revenue growth of 38.3% demonstrates continued momentum.
Bear Case : NVS
The primary concerns for NVS are Revenue Growth, Altman Z-Score, Debt/Equity.
Bear Case : XERS
The primary concerns for XERS are EPS Growth, Market Cap, Profit Margin. A P/E of 116.1x leaves little room for execution misses. Debt-to-equity of 2.87 is elevated, increasing financial risk.
Key Dynamics to Monitor
NVS profiles as a value stock while XERS is a hypergrowth play — different risk/reward profiles.
XERS carries more volatility with a beta of 0.85 — expect wider price swings.
XERS is growing revenue faster at 38.3% — sustainability is the question.
NVS generates stronger free cash flow (5.6B), providing more financial flexibility.
Bottom Line
NVS scores higher overall (51/100 vs 33/100), backed by strong 22.5% margins. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Novartis AG ADR
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Novartis AG researches, develops, manufactures and markets medical devices worldwide. The company is headquartered in Basel, Switzerland.
Visit Website →Xeris Pharmaceuticals Inc
HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA
Xeris Pharmaceuticals, Inc., a specialty pharmaceutical company, develops and markets ready-to-use injectable and infusible drug formulations. The company is headquartered in Chicago, Illinois.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?